Dr. Elledge is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7979 Wurzbach Rd
San Antonio, TX 78229Phone+1 210-450-1000Fax+1 210-450-1000
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1989 - 1992
Methodist Health System DallasResidency, Internal Medicine, 1987 - 1989- Methodist Health System DallasResidency, Internal Medicine, 1981 - 1984
McGovern Medical School at UTHealthClass of 1981
Certifications & Licensure
TX State Medical License 1981 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Bexarotene in Preventing Breast Cancer in Women at Genetic Risk Start of enrollment: 2001 Sep 01
Publications & Presentations
PubMed
- 111 citationsbcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.Richard M. Elledge, S. Green, L. Howes, Gary M. Clark, M. Berardo
Journal of Clinical Oncology. 1997-05-01 - 379 citationsEstrogen Receptor–Positive, Progesterone Receptor–Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen ResistanceGrazia Arpino, Heidi L. Weiss, Adrian V. Lee, Rachel Schiff, Sabino De Placido
Journal of the National Cancer Institute. 2005-09-07 - 158 citationsEpidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.Mothaffar F. Rimawi, Priya B. Shetty, Heidi L. Weiss, Rachel Schiff, C. Kent Osborne
Cancer. 2010-03-01
Press Mentions
Researchers Uncover New Clues to Why BRCA1 Mutations Cause Breast and Ovarian CancerJuly 19th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
